Other Clinical Trial - Study to Evaluate the Efficacy & Safety of APL-2 in

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04432584` - A Study Evaluating The Safety, Pharmacokinetics, and Efficacy Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors	Phase 3
Completed	`NCT05828485` - Effect of Food on Pharmacokinetics of MY008211A Tablets in Healthy Adult Subjects	Phase 1
Recruiting	`NCT02179359` - Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies	N/A
Active, not recruiting	`NCT04434092` - A Phase III Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors.	Phase 3
Terminated	`NCT05131204` - Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria	Phase 3
Recruiting	`NCT01374360` - Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry
Active, not recruiting	`NCT05389449` - A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH	Phase 3
Recruiting	`NCT06100900` - Dose Escalation of BCX10013 in Subjects With Paroxysmal Nocturnal Hemoglobinuria	Phase 1
Completed	`NCT01272817` - Nonmyeloablative Allogeneic Transplant	N/A
Completed	`NCT06326814` - A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy Adults	Phase 1
Completed	`NCT04463056` - Efficacy and Safety of Elizaria® vs. Soliris® in Patients With PNH	Phase 3
Recruiting	`NCT05476887` - To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104	Phase 2
Completed	`NCT01192399` - Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients	Phase 2
Active, not recruiting	`NCT06051357` - Proof of Concept Study to Assess the Efficacy, Safety of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria	Phase 2
Recruiting	`NCT06154512` - A Real-world, Multi-center, Prospective, Observational Study for PNH in China
Completed	`NCT04128943` - Electronic Patient-reported Outcome Monitoring in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
Active, not recruiting	`NCT03329365` - Paroxysmal Nocturnal Hemoglobinuria in ESUS & ETUS
Recruiting	`NCT05755867` - Global PNH Patient Registry
Completed	`NCT04679103` - A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC "GENERIUM", Russian Federation)	Phase 3
Completed	`NCT05642585` - A Study of Single-dose MY008211A in Healthy Adults	Phase 1

NCT number	NCT03500549
Study type	Interventional
Source	Apellis Pharmaceuticals, Inc.
Contact
Status	Completed
Phase	Phase 3
Start date	June 14, 2018
Completion date	August 13, 2020

Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms